Untapped therapeutic potential of surfactant proteins: is there a case for recombinant SP-D supplementation in neonatal lung disease?
Untapped therapeutic potential of surfactant proteins: is there a case for recombinant SP-D supplementation in neonatal lung disease?
Whilst pulmonary surfactant therapy has been highly successful in reducing mortality from respiratory distress syndrome of the newborn, a significant proportion of infants born at less than 28 weeks' gestation develop neonatal chronic lung disease. This has a complex pathogenesis but infection, inflammation, oxygen toxicity and ventilator-induced lung injury in the premature infant are all recognised risk factors for its development. Current surfactant therapies in clinical use do not contain all surfactant components and lack the hydrophilic surfactant proteins A and D. These proteins are known to have important roles in surfactant homeostasis and in protecting the lung against inflammation. This review examines the evidence from animal models supporting a role for surfactant protein-D in particular in reducing inflammation in the lung and speculates that supplementation of current surfactant therapies with recombinant forms of surfactant protein-D may help offset the risk of development of chronic lung disease.
respiratory distress syndrome, surfactant, chronic lung disease, surfactant protein-D, surfactant protein-A, pulmonary inflammation
380-387
Clark, Howard W.
70550b6d-3bd7-47c6-8c02-4f43f37d5213
June 2010
Clark, Howard W.
70550b6d-3bd7-47c6-8c02-4f43f37d5213
Clark, Howard W.
(2010)
Untapped therapeutic potential of surfactant proteins: is there a case for recombinant SP-D supplementation in neonatal lung disease?
Neonatology, 97 (4), .
(doi:10.1159/000297770).
(PMID:20551708)
Abstract
Whilst pulmonary surfactant therapy has been highly successful in reducing mortality from respiratory distress syndrome of the newborn, a significant proportion of infants born at less than 28 weeks' gestation develop neonatal chronic lung disease. This has a complex pathogenesis but infection, inflammation, oxygen toxicity and ventilator-induced lung injury in the premature infant are all recognised risk factors for its development. Current surfactant therapies in clinical use do not contain all surfactant components and lack the hydrophilic surfactant proteins A and D. These proteins are known to have important roles in surfactant homeostasis and in protecting the lung against inflammation. This review examines the evidence from animal models supporting a role for surfactant protein-D in particular in reducing inflammation in the lung and speculates that supplementation of current surfactant therapies with recombinant forms of surfactant protein-D may help offset the risk of development of chronic lung disease.
This record has no associated files available for download.
More information
Published date: June 2010
Keywords:
respiratory distress syndrome, surfactant, chronic lung disease, surfactant protein-D, surfactant protein-A, pulmonary inflammation
Identifiers
Local EPrints ID: 158721
URI: http://eprints.soton.ac.uk/id/eprint/158721
ISSN: 1661-7800
PURE UUID: 978c5b1b-7323-46d3-b108-8af40cdd3dde
Catalogue record
Date deposited: 22 Jun 2010 15:35
Last modified: 14 Mar 2024 01:52
Export record
Altmetrics
Contributors
Author:
Howard W. Clark
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics